Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down – Here’s What Happened

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s share price gapped down prior to trading on Friday . The stock had previously closed at $17.79, but opened at $17.17. Daiichi Sankyo shares last traded at $17.17, with a volume of 1,186 shares.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on DSNKY. Jefferies Financial Group downgraded shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. Zacks Research downgraded shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Monday, August 3rd. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

Daiichi Sankyo Stock Down 1.7%

The firm has a market cap of $32.06 billion, a price-to-earnings ratio of 20.01, a PEG ratio of 3.43 and a beta of -0.18. The firm has a 50 day moving average of $16.66 and a 200 day moving average of $17.46. The company has a quick ratio of 1.64, a current ratio of 2.42 and a debt-to-equity ratio of 0.18.

Daiichi Sankyo (OTCMKTS:DSNKY) last posted its quarterly earnings results on Friday, July 31st. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo had a return on equity of 14.22% and a net margin of 10.92%.Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. As a group, sell-side analysts predict that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.87 earnings per share for the current year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.